Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is expected to report third quarter earnings results, before market open, on Thursday 29th October 2020.
Analysts polled by Thomson Reuters anticipate third quarter income of $ 2.60 per share.
Looking ahead, the full year income are expected at $ 11.30 per share on the revenues of $ 5750.88 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 5,550.00 million ~ $ 5,600.00 million, where as bottomline are predicted in a range of $ 10.65 ~ $ 10.95 per share
Click Here For More Historical Outlooks Of Alexion Pharmaceuticals, Inc.
Previous Quarter Performance
Alexion Pharmaceuticals, Inc. communicated income for the second quarter of $ 3.11 per share, from the revenue of $ 1,444.60 million. The quarterly earnings extended 17.80 percent while revenues up 20.05 percent compared with the same quarter last year.
Wall street analysts are predicting, ALXN to report 2Q20 income of $ 2.59 per share from revenue of $ 1279.24 million. The bottom line results beat street analysts by $ 0.52 or 20.08 percent, at the same time, top line results outshined analysts by $ 165.36 million or 12.93 percent.
Stock Performance
Shares of Alexion Pharmaceuticals, Inc. traded low $ -5.15 or -4.29 percent on Wednesday, reaching $ 114.85 with volume of 1.81 million shares. Alexion Pharmaceuticals, Inc. has traded high as $ 118.76 and has cracked $ 114.83 on the downward trend
According to the previous trading day, closing price of $ 114.85, representing a 65.13 % increase from the 52 week low of $ 72.67 and a 6.67 % decrease over the 52 week high of $ 128.57.
The company has a market capital of $ 25.17 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Alexion Pharmaceuticals, Inc. will be hosting a conference call at 8:00 AM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.alexion.com
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
